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Background: Case-controlled studies have clearly demonstrated a link between chronic hepatitis C infection (CHC)
and B cell non-Hodgkin lymphoma (NHL). To our knowledge, this is the first case report of outcome in a patient
with CLL and chronic HCV infection treated with PEG-IFN/RBV and subsequent retreated with triple therapy.
Findings: We report the case of a 54-year old, caucasian woman with a history of elevated liver enzymes diagnosed
with chronic lymphocytic leukaemia (CLL) detected during investigation for hepatitis C (HCV) infection. The patient
showed a haematological response following initially successful anti-HCV therapy with peginterferon plus ribavirin
(PEG-IFN/RBV), with normalization of leukocyte and lymphocyte counts. She subsequently showed a late virological
relapse at week 24, and was successfully retreated with telaprevir-based triple therapy. Despite an increase in
leucocyte and lymphocyte count compared to baseline following triple therapy, to date there is no evidence of
progression of CLL and the patient remains asymptomatic.
Conclusion: Patients with CLL may experience haematological response following successful anti-HCV therapy
using IFN-based regimens. Re-treatment with triple therapy including telaprevir following late virological relapse
was successful, was not associated with any unexpected safety issues, and did not adversely affect CLL status.
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Case-controlled studies have clearly demonstrated a
link between chronic hepatitis C infection (CHC) and B
cell non-Hodgkin lymphoma (NHL) [1]. This evidence
has been supported by an increasing number of reports
showing a relationship between haematological response
in patients with a range of NHLs and sustained virological
response (SVR) following interferon (IFN)-based anti-
hepatitis C virus (HCV) therapy [2-4]. Although rare, viro-
logical relapse following a sustained response post-treatment
with IFN-based therapy does occur [5]. Recent treatment
guidelines recommend the use of triple therapy with* Correspondence: christensen@cim-ms.de
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article, unless otherwise stated.peginterferon plus ribavirin (PEG-IFN/RBV) and either
telaprevir or boceprevir (approved for use in Germany in
2011) in both treatment-naive genotype-1 infected pa-
tients and for those who have failed previous PEG-IFN/
RBV therapy [6,7]. The effect of recombinant interferons
on B-lymphocytic lymphoma is well known for years [8]
and recent studies show that aberrant interferon-signaling
is associated with aggressive CLL [9]. To date, there are
no reports of the use of triple therapy for chronic HCV in-
fection in patients with NHL.
We present a report of a case of chronic lymphocytic
leukaemia (CLL) in the context of chronic HCV infection
treated with PEG-IFN/RBV, and subsequently retreated
with triple therapy following late virological relapse.Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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A 54 year old, caucasian woman with a 12 year history of
elevated liver transaminases was referred for investigation
in March 2010. The patient complained of recurrent ver-
tigo but was otherwise asymptomatic. Her medical history
included arterial hypertension diagnosed 5 years previ-
ously and managed using bisoprolol, ramipril and lercan-
dipin. She was a non-smoker, did not drink alcohol, and
had no known allergies. Her surgical history comprised
appendectomy and tonsillectomy in childhood, and sur-
gery for a prolapsed intervertebral disc and breast reduc-
tion surgery, both approximately 15 years previously.
Initial testing revealed that the patient was anti-HCV
positive. Further testing showed genotype 1b CHC infec-
tion, interleukin (IL) 28B C/T and inosine triphosphatase
(ITPA) CC/AA genotypes, and a low viral load (HCV RNA
53049 IU/mL; HCV Abbott RealTime PCR version 4.0,
lower limit of quantification 12 IU/mL; Abbott GmbH &
Co., Wiesbaden, Germany). Gamma-glutamyl transpepti-
dase (gamma-GT) levels were found to be elevated (62 U/L,
normal >39 U/L) as were her alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) (88 U/l and 76
U/L, respectively; normal for both <35 U/L) levels. Other
liver function indicators including albumin, international
normalised ratio (INR) and serum cholinesterase activity
(CHE) were normal. Transient elastography (FibroScan®)
showed liver stiffness of 11.6 KPa, indicative of fibrosis (F3),
although this may have been overestimated due to the pres-
ence of non-alcoholic steatohepatitis on ultrasound.
In addition to the diagnosis of CHC, the patient was
incidentally found to have leucocytosis (15900/μl) and
lymphocytosis (8200/μl). Bone marrow biopsy confirmed
a diagnosis of CD20- and CD78-positive CLL with 5-
10% infiltration of the bone marrow, Binet stage A. The
patient was asymptomatic and no treatment for CLL
was indicated at this timepoint.
Given the patient’s age and fibrosis grade, her willing-
ness to undergo therapy and uncertainty associated with
the possible progression of her CLL, it was decided to
initiate antiviral treatment in August 2010 with peginter-
feron (PEG-IFN) alfa-2a (PEGASYS®; Roche Pharma AG,
Grenzach-Wyhlen, Germany) 180 μg/weekly plus ribavirin
(RBV; COPEGUS®; Roche Pharma AG, Grenzach-Wyhlen,
Germany) 1000 mg/day. At this time, neither telaprevir nor
boceprevir were approved for HCV infection in Germany.
On-treatment, her viral load declined to 818 IU/mL by
week 4 and was undetectable by week 12, consistent
with a complete early virological response (cEVR). Her
transaminases remained elevated (ALT 64 U/L; AST 65
U/L). Leucocytes decreased to 4600/μl with lymphocyte
count 2346/μL. On treatment, the patient experienced
anaemia (haemoglobin 10 g/dL) which was managed
without RBV dose reduction, and hypothyroidism with
elevated thyroid-stimulating hormone (TSH) levels inthe absence of detectable antibodies, which was treated
with L-Thyroxine 50 μg/d.
At end of treatment (Week 48) and at Week 12 post-
treatment, viral levels remained below limit of detection
(SVR12). At week 12 liver transaminases were slightly el-
evated (ALT 37 U/L; AST 43 U/L), and both leucocytes
(9600/μl) and lymphocytes (3216/μL) were within the
normal range. A control bone marrow biopsy performed
one month later showed immunhistochemical evidence
of nodular lymphocyte infiltrates as residue of a small-
cell lymphocytic B-cell lymphoma with infiltration dens-
ity of 25% without evidence of transformation to large
cell lymphoma.
In January 2012, 24 weeks post-treatment, there was an
increase in HCV RNA (102817 IU/mL) with elevated ALT
(55 U/L) and AST (52 U/). As there was no indication of
any risk for re-infection, the patient was diagnosed with
late relapse. At this time, leucocytes (7800/μl) and lym-
phocytes (3260/μL) remained within the normal range.
As the patient was still willing to undergo therapy, re-
treatment with a triple therapy regimen was initiated in
March 2012. At this time her liver stiffness by FibroScan®
was 9.2 KPa (F2/F3). The patient initially received PEG-
IFN alfa-2a 180 μg/week plus RBV 1000 mg/d plus tela-
previr (Incivo®; Janssen Cilag International NV, Beerse,
Belgium) 750 mg every 8 hours. After 12 weeks of triple
therapy, treatment was continued with PEG-IFN alfa 2a
plus RBV alone for a further 12 weeks (total treatment
duration 24 weeks). On treatment, her viral load declined to
12 IU/mL after 14 days and was below limit of detection by
week 4. In week 2, RBV dose was reduced to 800 mg/day
following a decline in haemoglobin by 2.6 g/dL to 10.3 g/dL;
PEG-IFN alfa 2a dose remained unchanged throughout
treatment. There was no requirement for growth factors
or for erythrocyte concentrates. Side effects of treatment
included nausea, recurrent vomiting, fatigue, and mood
changes, including depressive symptoms which were man-
aged using citalopram. The patient experienced a localized
skin reaction with itching on her back early in triple ther-
apy which was easily managed with corticosteroids, and
was no longer a problem after week 12.
Post-treatment, HCV RNA remained undetectable at
both Week 12 and Week 24 (SVR12 and SVR24), and
ALT and AST levels were within the normal range. How-
ever, the patient developed leucocytosis (13100/μL) again
with a lymphocyte count of 6485/μL. There was no evi-
dence for progression of CLL and the patient remained
clinically asymptomatic.
At her most recent presentation (March 2013), the pa-
tient’s HCV RNA levels remain undetectable, and her liver
enzymes are within normal ranges. Although her leuco-
cyte and lymphoctye counts remain elevated, she is still
asymptomatic, with has no indication for CLL therapy and
continues under observation by her haemato-oncologist.
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To our knowledge, this is first report describing the out-
come of a patient with CLL and CHC with a late viro-
logical relapse after dual combination treatment with
PEG-IFN plus ribavirin, and retreatment with triple
therapy including telaprevir leading to a sustained viro-
logical response. In addition, this case report empha-
sizes the importance of post-treatment monitoring of
response to therapy with PEG-IFN plus ribavirin, and
describes successful retreatment with triple therapy fol-
lowing a late relapse.
There is growing evidence from a number of large
case-controlled studies of an association between HCV
infection and the development of non-Hodgkin lymph-
oma (NHL) [1]. This link is particularly strong for B-cell
NHL including diffuse large B lymphoma, marginal zone
lymphoma and small lymphocytic lymphoma/CLL. HCV
prevalence has been reported to be around 15% in pa-
tients with B-cell NHL, compared with 1.5% in the gen-
eral population, although there is marked geographic
variation [10,11]. In a meta-analysis of case-controlled
studies, HCV infection was found to be strongly associ-
ated with risk of NHL, with an odds ratio of 5.04 (95%
confidence interval (CI), 4.09-7.96, P < 0.001) [12]. Add-
itional evidence for an association between HCV infection
and NHL comes from a number of studies reporting the
effect of antiviral therapy on lymphoma. Complete or par-
tial haematological remission has been reported following
IFN-based therapy for B cell NHLs, particularly in mar-
ginal zone lymphomas [2-4]. In a study of patients with a
range indolent B-cell NHLs, more patients achieved a re-
sponse (complete or partial) following treatment with
PEG-IFN/RBV (80%) compared with convention IFN/RBV
[4]. Haematological response has been shown to be linked
to achievement of an SVR, and to be maintained as long as
HCV infection does not reoccur [3,4]. No response to IFN
is reported in a systematic review of Gisbert et al. in HCV-
negative patients with lymphoproliferative diseases, indicat-
ing that the response in HCV-positive patients is clearly
not merely due to antiproliferative effects of IFN [3].
To our knowledge, there is currently only a single report
in the literature of CLL with hepatic involvement and
HCV infection which responded to PEG-IFN therapy [13].
In keeping with reports in other patients with B cell NHL,
the disappearance of HCV RNA during initial PEG-IFN/
RBV treatment in our patient was associated with a haem-
atological response in the patient’s CLL, which was main-
tained post-treatment. Although Interferon is not part of
the standard therapy anymore, our observations are in line
with several older studies which showed some treatment
effects of interferon in CLL resulting in a haematological
response [14-16]. This haematological response persisted
at post-treatment week 24, where virological relapse was
detected. Retreatment with triple therapy with telaprevirplus PEG-IFN/RBV following virological relapse did not
result in any safety issues with respect to the patient’s
CLL. Although the patient’s leucocytes and lymphocytes
were elevated following triple therapy despite a sustained
virological response, there remains no indication of pro-
gression of her CLL and she remains asymptomatic with-
out treatment. It is unclear why the ongoing sustained
virological response in our patient following triple therapy
has not been associated with a similar haematological re-
sponse as was seen following PEG-IFN/RBV alone.
The late virological relapse seen after PEG-IFN/RBV
therapy emphasizes the importance of post-treatment mon-
itoring. Late relapse is rare (<1%) following SVR at 24 weeks
post-treatment (SVR24) and achievement SVR24 is gener-
ally regarded as a ‘cure’ following IFN-based therapy, associ-
ated with improvements in liver histology, liver-related
morbidity and mortality [17]. There has been support for
using 12 week post-treatment response to indicate SVR,
and the Federal Drug Agency (FDA) now recommends use
of SVR12 as the primary end point for HCV clinical trials
[5,18,19]. However, relapse between post-treatment week
12 and 24 was seen in around 2% of patients overall and
5% of genotype 1-infected patients [5]. While SVR12 may
be relevant in registrational clinical trials, in the clinic con-
tinued monitoring at week 24 post-treatment is still rele-
vant to identify those rare patients, such as ours, with later
relapse, to allow for early retreatment where applicable.
Conclusions
As in other NHLs, patients with CLL may experience
haematological response following successful anti-HCV
therapy using IFN-based regimens. Re-treatment with
triple therapy including telaprevir following late virological
relapse was successful, was not associated with any unex-
pected safety issues, and did not adversely affect CLL
status.
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